Biuk Dubravka, Karin Anita Alegić, Matić Suzana, Barać Josip, Benasić Tvrtka, Stiglmayer Neda
'J. J. Strossmayer" University, Osijek University Hospital Center, Department of Ophthalmology, Osijek, Croatia.
Coll Antropol. 2013 Mar;37(1):29-33.
The aim of this prospective study was to analyse the quality of life in patients with blepharospasm grade III and IV and to explore whether Botulinum neurotoxin type A treatment improves their quality of life. We used a WHOQOL-BREF questionnaire, based on the existing WHO recommendation and its meaningful metric characteristics. The study included 37 patients with either grade/type III or IV blepharospasm who were treated with Botulinum neurotoxin Type A. Each patient completed the WHOQOL-BREF questionnaire by themselves just before the Botulinum Neurotoxin Type A (BT-A) therapy application, when the clinical symptoms of blepharospasm were most manifest and a month and a half after, when the regression of symptoms appeared. Consequently, the application of BT-A resulted in improved changes in terms of quality of life in 3 of the 4 measured fields (psychical and physical health as well as the environmental living conditions).
这项前瞻性研究的目的是分析III级和IV级眼睑痉挛患者的生活质量，并探讨A型肉毒杆菌神经毒素治疗是否能改善他们的生活质量。我们使用了基于世界卫生组织现有建议及其有意义的度量特征的WHOQOL-BREF问卷。该研究纳入了37例III级或IV级眼睑痉挛患者，他们接受了A型肉毒杆菌神经毒素治疗。每位患者在A型肉毒杆菌神经毒素（BT-A）治疗应用前，即眼睑痉挛临床症状最明显时，以及症状消退一个半月后，自行完成WHOQOL-BREF问卷。因此，BT-A的应用在4个测量领域中的3个（心理健康、身体健康以及环境生活条件）导致了生活质量的改善变化。
